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Abstract: The gastrointestinal tract harbors the gut microbiota, structural alterations of which (dys-
biosis) are linked with an increase in gut permeability (“leaky gut”), enabling luminal antigens and
bacterial products such as nanosized bacterial extracellular vesicles (BEVs) to access the circulatory
system. Blood-derived BEVs contain various cargoes and may be useful biomarkers for diagnosis
and monitoring of disease status and relapse in conditions such as inflammatory bowel disease (IBD).
To progress this concept, we developed a rapid, cost-effective protocol to isolate BEV-associated
DNA and used 16S rRNA gene sequencing to identify bacterial origins of the blood microbiome of
healthy individuals and patients with Crohn’s disease and ulcerative colitis. The 16S rRNA gene
sequencing successfully identified the origin of plasma-derived BEV DNA. The analysis showed
that the blood microbiota richness, diversity, or composition in IBD, healthy control, and protocol
control groups were not significantly distinct, highlighting the issue of ‘kit-ome’ contamination in
low-biomass studies. Our pilot study provides the basis for undertaking larger studies to determine
the potential use of blood microbiota profiling as a diagnostic aid in IBD.
Keywords: extracellular vesicles; gut bacteria; inflammatory bowel disease; dysbiosis; microbiota;
plasma; 16S rRNA
1. Introduction
The human body harbors on average 3.8 × 1013 microbes, termed the microbiota [1],
the largest community of which resides in the gastrointestinal tract (GIT). Comprising
bacteria, viruses, fungi, protozoa, and archaea, the intestinal microbiota contributes to the
life-long health of the host, playing key roles in digestion, the provision of essential amino
acids and micronutrients, and in the maturation and maintenance of the host immune
system as well as maintaining intestinal epithelial barrier integrity [2]. Associations have
been demonstrated between an altered structural composition of the microbiota (dysbiosis)
and many human diseases [3], in particular, those with a concomitant “leaky gut” and
increased permeability of the intestinal barrier as seen in inflammatory bowel disease
(IBD) [4]. IBD is a debilitating group of chronic diseases which causes relapsing–remitting
inflammation of the GIT and affects millions of people worldwide [5]. IBD is primarily
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categorized into two diseases: Crohn’s disease (CD), which encompasses inflammation
throughout the GI tract, or ulcerative colitis (UC), which affects primarily the colon.
The intestinal microbiota of IBD patients characteristically shows reduced bacterial
richness with a phylum-level decreased abundance of Firmicutes and associated increased
abundance of Proteobacteria compared to individuals without IBD [6]. Whether this dys-
biosis contributes to intestinal inflammation and if it causes increased intestinal barrier
permeability is not known [7]. Increased permeability of the epithelial barrier enables
luminal dietary antigens and microbial products, such as lipopolysaccharide (LPS) and
other microbe associated molecular pattern (MAMP) molecules and nanosized bacterial
extracellular vesicles (BEVs) expressing an array of MAMPs, to access the underlying
lamina propria and vasculature [8]. The translocation of MAMPS into the blood stream
can lead to increased systemic immune activation and the chronic gut inflammation that is
characteristic of IBD [9].
BEVs are naturally produced by both Gram-negative and Gram-positive bacteria as a
result of budding or blebbing of inner/outer cell membranes or explosive cell lysis [10,11].
As BEVs form, they encapsulate cytoplasmic and/or periplasmic proteins, enzymes, RNA,
and DNA via incompletely understood selective sorting processes [12–14]. Some studies
suggest that environmental factors and stressors encountered by the parental cells strongly
influence the nature of BEV cargo [15]. The physiochemical properties of BEVs and their
inherent resistance to physical, chemical, and biological insults make them ideal drug
delivery vehicles in the hostile environment of the GIT, facilitating the delivery of their
cargo to specific cells and locations within the host [16]. This role of BEVs was first
elucidated for Gram-negative pathogens which use the BEVs they generate to deliver
toxins and virulence factors to breach host defenses and allow parental cells to invade and
establish infection within the host [8]. For commensal Gram-negative bacteria, the role
BEVs play in microbe–microbe and microbe–host interactions is only just becoming clear.
For example, we and others have shown that major human gut commensal Bacteroides
spp., including Bacteroides thetaiotaomicron, generate BEVs expressing hydrolases and β-
lactamases that can promote the growth or protect other gut bacteria from otherwise fatal
doses of antibiotics, respectively [17,18]. They can also initiate host immune responses via
their interaction with antigen presenting cells [19] and cross the intact intestinal epithelial
barrier to reach distant tissues such as the liver and kidneys [20], suggesting BEVs play a
key role as both short and long-distance delivery vehicles for bacterial effector molecules.
A “leaky gut” is thought to precede the onset of disease symptoms, and patients with
quiescent IBD and their family members often have subclinical intestinal inflammation [21].
Therefore, detection of a compromised gut barrier could provide an earlier diagnosis for
patients and interventions that can halt the development of IBD symptoms. Current meth-
ods of IBD diagnosis require the presentation of intestinal inflammatory disease symptoms
and often requires many tests for inflammatory biomarkers such as fecal calprotectin or
C-reactive protein (CRP) alongside invasive investigations such as an endoscopy and
biopsy samples [22]. However, these standard biomarkers can be insensitive, potentially
reflecting inflammatory conditions of unknown origin. Therefore, comparing the presence
of BEVs in the blood of both healthy individuals and those with diseases associated with a
“leaky gut” holds the potential for clinical applications as novel biomarkers.
Consequently, a number of studies using DNA (16S rRNA) sequencing have inves-
tigated the origin of the “blood microbiome”, indicating that the blood microbiome of
healthy individuals comprises of DNA originating from mainly Proteobacteria, Actinobacteria,
Firmicutes, and Bacteroidetes [23], although the source of this circulating DNA is often not de-
scribed. BEV-associated DNA has been identified in patients with Alzheimer’s disease [24],
Parkinson’s disease [25], dermatitis [26], asthma [27], cardiovascular disease [28], gastric
cancer [29], biliary tract cancer [30], and COVID-19 [31]. However, few have investigated
the origin of blood-derived BEVs in IBD. In a recent study aiming to define the biological
properties of BEVs, Tulkens and colleagues described an increase in LPS-positive BEVs in
the plasma of patients with intestinal barrier dysfunction, including those with IBD [32],
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independently of BEV-associated DNA. As the number of studies of BEVs in biological
fluids such as blood increases, there is a growing need for universal, standard isolation
methods, particularly for the isolation of BEV-associated DNA from low-biomass samples
such as plasma.
In this pilot study, we obtained a small number of plasma samples from healthy
controls (HC) and a cohort of patients with an established diagnosis of Crohn’s disease
(CD) and ulcerative colitis (UC) [33]. Our aim was to develop a fast, easy, and cost-effective
method to isolate BEV-associated DNA from plasma to investigate the origin of the blood
microbiota in IBD and HC samples. Samples were characterized by nanoparticle tracking
analysis (NTA), protein analysis, and transmission electron microscopy (TEM) imaging.
EV isolation methods were compared in an initial experiment prior to the main study.
Using 16S rRNA gene sequencing, we found that there was no difference in the BEV-
associated blood microbiota richness, diversity, or composition between IBD, HC, and proto-
col control groups, highlighting the issue of ‘kit-ome’ contamination in low-biomass studies.
2. Materials and Methods
2.1. Study Design
Archived plasma samples from a cohort of individuals enrolled in a study looking at
microbiota immunity in IBD were used for this pilot study [33]. As previously described
by Noble et al., patient samples were obtained from outpatient clinics at St Mark’s Hospital
at Northwick Park Hospital, Harrow, UK, and included those with a diagnosis of Crohn’s
disease (CD) or ulcerative colitis (UC). No patients were experiencing active, symptomatic
disease at the time of sampling. Healthy control (HC) samples were obtained from indi-
viduals undergoing investigative endoscopy or from hospital staff and visitors. No HC
individuals had a diagnosis of IBD. Plasma samples (4–5 mL) were obtained from a total of
23 individuals: 7 HC, 8 CD, and 8 UC (Table 1). All samples were stored at −80 ◦C prior to
analysis. It should be noted that corresponding biomarkers for inflammation associated
with IBD, such as fecal calprotectin, were not available for the samples used in this study.
Table 1. Patient characteristics. Clinical characteristics and demographics of St Mark’s Hospital
blood donors and healthy volunteers [33].
Characteristic HC 1 CD 2 UC 3
n 7 8 8
Male/female 5/2 3/5 5/3
Mean age at sampling 44 (28–57) * 49 (24–73) * 56 (41–71) *
Mean age at diagnosis 37 (19–61) * 40 (24–53) *
Symptoms at sampling:
Diarrhea/loose stools 3 2
Abdominal pain/bloating/flatulence 0 1
Peri-anal pain/itch/disease 1 1
Anal fissure/bleed/proctitis 1 2
None 5 3
Medications at sampling:
IBD 4 medications 6 6
Non-IBD medications 1 3
None 1 1
1 Healthy control (HC), 2 Crohn’s disease (CD), 3 ulcerative colitis (UC) and 4 inflammatory bowel disease (IBD).
* Mean (range).
A further two HC samples were obtained to use for initial protocol optimization before
the main study whereby three EV isolation methods were compared to test 16S rRNA
gene amplification and assess the efficiency of DNase I pre-treatment and extracellular
protein removal.
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For the main 16S rRNA gene sequencing study, five protocol controls were included
for all stages of the protocol, including EV isolation, DNA extraction, and PCR to identify
any contamination introduced, with one step of the protocol being removed for each
sample: whole protocol, no boiling, no boiling or EV lysis, and PCR only (water or blank).
Protocol control samples are outlined in Appendix A Figure A1 and the study design is
outlined in Figure 1.
Figure 1. Study design overview. To characterize the BEV profile in HC and IBD plasma, archived samples from a cohort of
healthy individuals (seven HC) and patients diagnosed with IBD (eight CD and UC) were utilized alongside five control
samples representing each stage of the protocol. Two further HC samples were characterized and processed for protocol
optimization. Samples were analyzed for 16S rRNA gene sequencing and data processed using the Dadaist2 pipeline. The
processed data was analyzed using the MicrobiomeAnalyst web platform and evaluated using taxonomic profiling and
significance testing. Healthy controls (HC), Crohn’s disease (CD), and ulcerative colitis (UC). The number of samples used
at each stage of the study are indicated.
2.2. Nanoparticle Tracking Analysis
Plasma nanoparticle tracking analysis (NTA) was performed using a ZetaView TWIN
instrument according to manufacturer’s instructions (Particle Metrix GmbH, Inning am
Ammersee, Germany). ZetaView software (version 8.05.12 SP1) was used to run a 2 cycle
11 position high frame rate analysis at 25 ◦C. Sample dilutions were carried out in ultra-
pure water prior to analysis to fit within optimal detection range. Camera control settings:
80 sensitivity; 30 frame rate; 100 shutter. Post-acquisition parameters: 20 min brightness;
2000 max area; 5 min area; 30 trace length; 5 nm/class; 64 classes/decade.
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2.3. Protein Concentration Measurement
Plasma protein concentrations were determined using a BCA Protein Assay Kit for
low concentrations according to manufacturer’s instructions (Abcam, Cambridge, UK).
Absorption was measured at 562 nm using a FLUOstar Plate Reader (BMG Labtech, Bucks,
UK). All samples and standard controls were measured in duplicate.
2.4. Transmission Electron Microscopy
Plasma samples were visualized using negative staining with TEM. Briefly, 5 µL
plasma diluted 1:10 in PBS were adsorbed to carbon-formvar coated copper EM grids
(Agar Scientific, Essex, UK) for 30 s (un-processed) or 1 min (processed using SEC or
boiling) before wicking off with filter paper and negatively staining with 2% Sodium
(K) phosphotungstate solution (processed using SEC or boiling) or 0.5% Uranyl Acetate
(unprocessed) for 1 or 2 min respectively. Grids were air dried before analysis using a FEI
Talos F200C electron microscope at 17,500–57,000×magnification with a Gatan OneView
digital camera. Images were processed using FIJI/ImageJ (v1.53c).
2.5. Extracellular Vesicle Isolation from Plasma
Plasma samples were thawed and centrifuged at 1500× g for 10 min at RT to remove
cells and large particles and filtered through a 0.22 µm syringe filter prior to treatment with
DNase I using a TURBO DNA-free Kit (Invitrogen, Loughborough, UK). EV isolation was
then optimized using one of the following methods:
2.5.1. Ultracentrifugation
Plasma samples (9 mL) were ultracentrifuged at 150,000× g for 2 h at 4 ◦C in a Ti70
rotor (Beckman Instruments, High Wycombe, UK) to pellet the EVs. The supernatant was
discarded and the pellet resuspended in sterile PBS for further analysis.
2.5.2. Size Exclusion Chromatography
Plasma samples (1 mL) were loaded onto a qEV/35 nm series size exclusion chromatog-
raphy (SEC) column and fractions obtained according to manufacturer’s instructions (IZON
Science, Lyon, France). Plasma BEVs typically elute in the 3 mL following the void volume
and proteins in later fractions, so fractions 1–6 were pooled for further analysis. An example
of HC plasma qEV SEC fractionation profile is provided in Appendix A Figure A2a.
2.5.3. Boiling
Plasma samples (1 mL) were boiled at 100 ◦C for 40 min in a thermomixer at 600 rpm
(Eppendorf) followed by centrifugation at 13,000× g for 30 min at 4 ◦C to remove extracel-
lular proteins.
For optimization of the EV isolation protocol, all three methods (UC, SEC, and boiling)
were compared. Following this, boiling was identified as the optimal method and all
further samples for the main 16S rRNA gene sequencing study were processed for EV
isolation by boiling only.
2.6. DNA Extraction and Quantification
Samples were concentrated using Amicon Ultra 0.5 centrifugal filters with regenerated
cellulose membranes and 10 kDa pore size (Millipore Limited, Feltham, UK) prior to
lysis using an optimal two-step process. They were first incubated with a 10% SDS lysis
buffer for 40 min at 37 ◦C followed by a second lysis step (lysis solution: guanidine
hydrochloride) and DNA isolation using the GeneJET Genomic DNA Purification Kit
according to manufacturer’s instructions (Thermo Fisher Scientific, Loughborough, UK).
Total genomic DNA was collected in a final 100 µL volume. DNA was quantified using a
Qubit 1× dsDNA High Sensitivity Kit (Thermo Fisher Scientific, Loughborough, UK).
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2.7. PCR and Gel Densitometry
To assess the efficiency of DNase I treatment to remove free DNA, plasma samples
were spiked with Bacillus subtilis (ATCC 6633) DNA, and PCR used to assess DNA removal
(before BEV lysis) using the strain specific primer pair: Bs_Fwd ACCATTGCGGTAGGT-
GCG and Bs_Rev GCGTTTGTCCAAGTCGGG [34]. For taxonomic profiling 16S, universal
primers targeted the V3–V4 region of the 16S rRNA gene [35] and included the over-
hang Illumina index and sequencing adaptors: Fwd: 5′ TCGTCGGCAGCGTCAGATGTG-
TATAAGAGACAG and Rev: 5′ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG.
V3–V4 locus-specific 16S_Fwd TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCC-
TACGGGNGGCWGCAG, and V3–V4 locus-specific 16S_Rev GTCTCGTGGGCTCGGA-
GATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC were used.
PCR products were separated by gel-electrophoresis and visualized under UV light
using Midori Green Direct (Geneflow Limited, Lichfield, UK). In all PCR assays, a mock
DNA extraction (water) and negative PCR control were included.
2.8. 16S rRNA Gene Sequencing
Library preparation was performed using a two-step PCR amplification, first using
Q5 High-Fidelity DNA Polymerase (New England Biolabs Limited, Hitchin, UK) and 16S
universal primers targeting the V3–V4 region of the bacterial 16S rRNA gene as outlined
above. The resulting single amplicon target of approximately ~460 bp was amplified
using a second limited cycle PCR adding Illumina sequencing adaptors and dual-index
barcodes. Samples were sequenced by Illumina MiSeq using paired 300 bp reads and
MiSeq v3 reagents.
2.9. Data Analysis
The 16S rRNA gene sequencing data was analyzed using the Dadaist2 v.1.0 pipeline [36],
which pre-processes the reads using Cutadapt 3.3 [37] to remove the locus specific primers,
fastp 1.2 [38] to produce SeqFu 1.4 [39] to identify the qualified regions for the identification
of the amplicon sequence variants (ASVs) using DADA2 [34]. The taxonomic classification
was performed within Dadaist2 using DECIPHER [40] against the SILVA database, release
138 [41].
Downstream analysis was performed using the MicrobiomeAnalyst web platform for
data processing, statistical analysis, and visual analysis (updated version 16 February 2021) [42].
Firstly, a data integrity check was performed and samples with a low total read count
(<100) were removed. Where the original data was used (relative abundance profiling,
diversity profiling, and significance testing as well as hierarchical clustering and heatmap
visualization), unfiltered data was scaled using total sum scaling (TSS). For α-diversity pro-
filing, data rarefying was performed to even sequencing depth based on the samples with
the lowest read counts. Where further filtering was performed to remove low abundance
reads for classical univariate analysis (CUA), a cut-off of >4 counts in >20% of samples was
used, and to remove low variance reads the cut-off was >10%. Visual data analysis was
performed using stacked bar plots and heatmap clustering.
2.10. Statistics
All data are presented as the mean ± standard deviation (SD) with the indicated
sample sizes. Using GraphPad Prism (v9.0.0), p-values for the relative taxa abundance were
calculated using ordinary one-way analysis of variance (ANOVA) followed by Dunnett’s
multiple comparisons test and Benjamini, Krieger and Yehotieli false discovery rate (FDR)
test. Using MicrobiomeAnalyst, α-diversity was measured using the Observed Index
(number of unique ASVs observed per sample) and one-way ANOVA to test differences
between groups. β-diversity was measured using Bray–Curtis dissimilarity index and
visualized using principal-coordinate analysis (PCoA) and differences between groups
tested using permutational multivariate analysis of variance (PERMANOVA). Taxon-wise
statistical comparisons of relative abundances were performed using CUA with either a
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t-test (two groups) or one-way ANOVA (>2 groups) to test differences between groups. The
false discovery rate (FDR) was set to 0.05. Statistically significant features were considered
when the corrected p-value < 0.05.
3. Results
3.1. Patient Characteristics
Participant demographics are shown in Table 1. Their ages ranged from 24 to 73 with
a mean age of healthy controls of 43.9 ± 11.0, 49.0 ± 16.2 for CD, and 56.0 ± 9.46 for UC.
Mean age of patients at IBD diagnosis was 36.6 ± 19.1 for CD and 39.9 ± 10.0 for UC. There
were no substantial differences between symptoms and medications between IBD groups.
3.2. Features of Plasma Nanoparticles
The concentration and size distribution of plasma-derived nanoparticles was deter-
mined using a ZetaView twin instrument for NTA. The average concentration of particles in
HC plasma was 2.8× 1012/mL with a heterologous hydrodynamic size range of 20–400 nm
in water (Figure 2a).
Figure 2. Characteristic features of plasma nanoparticles. Nanoparticle tracking analysis (NTA) was
performed using a ZetaView twin instrument. (a) The average concentration of particles in plasma is
2.8 × 1012/mL with a heterologous hydrodynamic size range of 20–400 nm and a mean particle size
of 94 nm in water. HC samples, n = 7. Points (black) represent the mean and the error bars (grey)
represent the standard deviation (SD). (b) Transmission electron microscopy (TEM) identified intact,
spherical vesicles in patient plasma with a heterogeneous size. Some of these particles displayed the
classic cup-shape morphology typical of negatively stained BEVs (inset figure). Scale bar 500 nm.
Although TEM could not be performed on unprocessed plasma due to the presence of
contaminating proteins (Appendix A Figure A2b), imaging of qEV SEC processed samples
confirmed the presence of intact, spherical vesicles in patient plasma (Figure 2b) with a
heterogeneous size, with the majority displaying a bilayer morphology [43,44]. A small
number of these particles were identified as having a classic cup-shaped morphology
typical of negatively stained BEVs identified by TEM (Figure 2b inset).
The proportion of plasma EVs of bacterial origin is challenging to quantify by mor-
phology from TEM imaging as they are generally indistinguishable from mammalian
plasma EVs [45,46]. The majority of BEVs form by budding of the outer membrane (re-
ferred to as outer membrane vesicles (OMVs) [10]) and contain a single lipid bilayer. A
small proportion forming outer-inner membrane vesicles (O-IMVs) containing a double
lipid bilayer have also been described [47,48]; however, no O-IMVs were identified in our
images. Further in-depth analysis is required for quantitative analysis using, for example,
cryo-TEM [49,50] or immuno-EM using specific marker antigens for BEVs [32].
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3.3. Optimising Bacterial Extracellular DNA Isolation from Plasma
To optimize the recovery of plasma-derived BEV DNA and remove contaminating
extracellular proteins, three EV isolation methods were compared: ultracentrifugation,
SEC (qEV columns), or boiling prior to processing all remaining samples with the chosen
optimal method. For each method, 1–2 additional HC plasma samples were used alongside
a protocol control sample (water).
Following the EV isolation step, samples were further concentrated using centrifugal
filters with regenerated cellulose membranes and a pore size of 10 kDa that have been
shown to be the most efficient for EV recovery; both from eukaryotic (mammalian) and
prokaryotic origin [51]. DNA was then isolated using the GeneJET Genomic DNA Pu-
rification Kit and after 16S rRNA gene amplification, densitometry of the corresponding
PCR products was compared per mL of plasma. The SEC and boiling methods both
showed higher 16S rRNA amplification than ultracentrifugation (Figure 3a). However, only
the boiling method identified significantly lower 16S rRNA amplification in the protocol
control (water, Figure 3a). This suggests the qEV SEC columns introduce bacterial DNA
contamination and are not suitable for downstream PCR amplification applications. TEM
imaging confirmed the reduction in extracellular protein aggregates (black arrowheads,
Figure 3c) after boiling. Taken together, these results identified the boiling method as the
optimal protocol for isolating BEVs for DNA extraction and this method was used for the
main 16S rRNA gene sequencing analysis.
Figure 3. Optimisation of plasma-derived BEV DNA isolation. (a) EV isolation protocol comparison
and densitometry of the corresponding PCR products per mL of plasma (AU). Ultracentrifugation
(UC; blue), size exclusion chromatography using qEV columns (SEC; red) and boiling (boil; green).
SEC and boiling methods show higher 16S rRNA gene amplification than ultracentrifugation. Only
the boiling method identified significantly lower 16S rRNA gene amplification in the protocol control
(water). The boiling method was identified as the optimal protocol for isolating BEVs for DNA
extraction and was used for the main 16S rRNA gene sequencing analysis. Sample n = 1–2. The
error bars represent the standard deviation (SD). (b) Extracellular DNA was eliminated from plasma
samples by pre-treatment with DNase I. Chromosomal DNA from B. subtilis was used to spike
plasma samples prior to DNase treatment to confirm the effectiveness of extracellular DNA removal
(non-lysed samples). Plasma samples were processed for DNA extraction and amplified using
primers specific for both B. subtilis (red) and the V3–V4 region of the 16S rRNA gene (blue). DNA
was amplified by both primer sets (B. subtilis DNA), which was subsequently eliminated by DNase
I treatment (plasma + DNA + DNase I) but not when DNase I was excluded from the reaction
(plasma + DNA). Sample n = 1, analysed in duplicate except for B. subtilis DNA positive control.
The error bars represent the standard deviation (SD). A faint 16S rRNA band corresponding to
extracellular DNA was detected in the plasma control sample (*) which was eliminated by DNase I
pre-treatment. (c) TEM imaging confirmed the reduction in extracellular protein aggregates (black
arrowheads) after boiling. Scale bar 200 nm.
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3.4. Identifying the Origin of Plasma Derived Bacterial Extracellular Vesicles by 16S rRNA
Gene Sequencing
Extracellular DNA was eliminated from plasma samples by pre-treatment with DNase
I. Chromosomal DNA from B. subtilis was used to spike one additional HC plasma sam-
ple prior to DNase treatment to confirm the effectiveness of extracellular DNA removal.
Samples were then processed for DNA extraction and amplified using primers specific
for both B. subtilis and the V3–V4 region of the 16S rRNA gene. Figure 3b shows that
DNA was amplified by both primer sets, which was subsequently eliminated by DNase I
treatment but not when DNase I was excluded from the reaction. A faint 16S rRNA band
corresponding to free extracellular DNA was detected in the plasma control sample which
was undetectable after DNase I pre-treatment (Figure 3b).
Due to the low-biomass nature of BEVs in plasma, low concentrations of DNA were
obtained from all the main study samples. The mean concentration of DNA extracted from
IBD plasma (CD 2.915 ng/mL ± 1.638 and UC 3.067 ng/mL ± 1.994) was comparable to
HC (2.790 ng/mL ± 2.096). One sample (UC5) was removed from further analysis as no
detectable DNA was extracted.
16S rRNA gene sequencing and taxonomic profiling was used to identify the origin
of circulating BEVs in HC, CD, and UC plasma. Sequence data were analyzed using the
Dadaist2 pipeline. Using MicrobiomeAnalyst, a total of 392,177 quality filtered amplicon
sequence variants (ASVs) were generated, with 14,525 ± 11,270 average reads per sample.
Two samples were removed from the analysis due to low read counts (HC5 and CD8).
The ASVs were mapped to 65 genera with the most dominant being Bradyrhizobium, Es-
cherichia/Shigella, Bacteroides, and Lysobacter (Figure 4a). A full list of taxa (ASV) abundance
is provided in Table S1.
Figure 4. Taxonomic profiles between protocol control samples and plasma are distinct. (a) The relative abundance chart
shows the top 10 most dominant taxa at the genus level. (b) Microbial richness measured by α-diversity in protocol controls
was lower than that of plasma samples in three cases but comparable to plasma in two (ASV-level Observed Index: number
of unique ASVs observed per sample). (c) The β-diversity PCoA plot shows that three protocol control samples (red) form
a cluster that is significantly distinct from the plasma samples; however, two samples cluster alongside plasma (blue)
(ASV-level; Bray–Curtis Index). Violin plot with individual values demonstrating frequency distribution: dotted lines
represent the upper and lower quartiles, and the central dashed line represents the median.
To identify 16S rRNA gene amplicons originating from DNA contamination during
sample processing, taxonomic profiles from protocol control samples and plasma were
compared. With respect to α-diversity (microbial richness), three controls (no boiling or
EV lysis, and PCR only (water), and PCR only blank) exhibited lower microbial richness
than the plasma samples, whereas two controls (whole protocol and no boiling) were
more comparable to plasma (ASV-level Observed Index: number of unique ASVs observed
per sample; Figure 4b). β-diversity (microbial community composition dissimilarity) was
visualized using a PCoA plot with Bray-Curtis Index and showed that the same three
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protocol control samples were significantly distinct from the plasma samples and two again
clustered with the plasma samples (ASV-level; Figure 4c).
The protocol control samples were designed to identify at which stage contamination
is introduced, with one step of the protocol being removed for each control sample. The
two protocol control samples that clustered alongside the plasma samples suggest that
contamination is introduced after the EV lysis steps. This can be visualized as an increase
in genera abundance (Appendix A Figure A1a,b) and microbial richness (α-diversity index:
Observed, ASV-level; Appendix A Figure A1c) in the whole protocol and no boiling
samples. Using CUA, significantly differential genera between plasma and the protocol
controls were identified as Lysobacter (FDR p-value: 0.000013938, Bacillus and Pseudomonas
(FDR p-values: 0.001606), and Xanthobacter (FDR p-value: 0.0020979), Limnobacter (FDR
p-value: 0.0028168), Acinetobacter (FDR p-value: 0.005619), Kocuria (FDR p-value: 0.0076808),
and Brachybacterium (FDR p-value: 0.015392) (Table S2).
Sequence-based filtering was performed to remove representative protocol control
reads with >20% prevalence in the plasma samples. Two further samples were removed
from the analysis due to low read counts (HC6 and CD1). A total of 14,864 ASVs were
identified from the filtered plasma-derived BEV samples, with 743 ± 586 average reads
per sample (Table S3). At the phylum level, the most abundant taxa were Proteobacteria,
Firmicutes, and Actinobacteria (Figure 5a).
The α-diversity analysis showed no significant difference in microbial richness be-
tween groups (ASV-level Observed Index and one-way ANOVA p-value: 0.89198; Figure 5b).
β-diversity analysis showed no significant differences in microbial community composi-
tion between the groups (ASV level PCoA plot with Bray–Curtis Index and permutational
MANOVA (PERMANOVA) p-value: 0.276; Figure 5c). The overall microbial composition
also did not reveal any differences at the phylum level (Proteobacteria, Firmicutes, and Acti-
nobacteria one-way ANOVA p-values: HC vs. CD 0.7044, 0.4811, and 0.6117, respectively;
HC vs. UC 0.9763, 0.9646, and 0.8331, respectively; FDR p-values: HC vs. CD 0.4954, 0.3127,
and 0.4148, respectively; HC vs. UC 0.8620, 0.8311, and 0.6269, respectively; Figure 5d).
Heat map clustering at the ASV level revealed 59 specific ASVs observed in all groups
(Figure 6). In HC, most highlighted taxa (red) were Proteobacteria including Brevundimonas
genus and Firmicutes including Bacillus, Enterococcus, Staphylococcus, and Streptococcus
genus. In CD and UC, they were Proteobacteria including Escherichia/Shigella, Paracoccus,
Xanthobacter, Pseudomonas, and Lysobacter genus as well as Actinobacteria including Brachy-
bacterium and Brevibacterium genus, and Firmicutes including Staphylococcus, Streptococcus,
Lactococcus, and Lactobacillus genus. However, these taxa were each typically found to be
elevated among only one member of each group and no differences between groups were
found to be statistically significant using CUA. A full list of taxa is provided in Table S4.
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Figure 5. Microbial diversity and richness. Sequence-based filtering was performed to remove repre-
sentative protocol control reads with >20% prevalence in the plasma samples. (a) The most abundant
taxa at the phylum level were Proteobacteria, Firmicutes, and Actinobacteria. (b) Microbial richness and
diversity were not significantly different between groups. The α-diversity plot shows no significant
difference between groups (ASV-level Observed Index: number of unique ASVs observed per sample
and one-way ANOVA p-value: 0.89198), and (c) the β-diversity PCoA plot also shows no signifi-
cant differences between the groups (ASV level: Bray-Curtis Index and permutational MANOVA
(PERMANOVA) p-value: 0.276). (d) There were also no significant changes in relative abundance
at the phylum level (Proteobacteria, Firmicutes, and Actinobacteria one-way ANOVA p-values: HC vs.
CD 0.7044, 0.4811, and 0.6117, respectively; HC vs. UC 0.9763, 0.9646, and 0.8331, respectively; FDR
p-values: HC vs. CD 0.4954, 0.3127, and 0.4148, respectively; HC vs. UC 0.8620, 0.8311, and 0.6269,
respectively. Violin plots with individual values demonstrating frequency distribution: dotted lines
represent the upper and lower quartiles, and the central dashed line represents the median. Healthy
controls (HC; red), Crohn’s disease (CD; blue), and ulcerative colitis (UC; green).
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Figure 6. Hierarchical clustering and heatmap visualization at the feature (ASV) level. Heatmap clus-
tering (Euclidean distance measure and Ward clustering algorithm) identified 59 ASVs observed in
all groups (HC, Red; CD, green; and UC, blue). In HC, most observed taxa (dark red) were Proteobac-
teria including Brevundimonas genus and Firmicutes including Bacillus, Enterococcus, Staphylococcus,
and Streptococcus genus. In CD and UC, most taxa were Proteobacteria including Escherichia/Shigella,
Paracoccus, Xanthobacter, Pseudomonas, and Lysobacter genus as well as Actinobacteria including Brachy-
bacterium and Brevibacterium genus, and Firmicutes including Staphylococcus, Streptococcus, Lactococcus,
and Lactobacillus genus.
4. Discussion
BEVs in body fluids such as plasma have not been as widely studied as mammalian
EVs, likely due to the difficulties associated with their isolation [52]. We developed a
rapid, cost-effective protocol to isolate BEV-associated DNA and used 16S rRNA gene
sequencing to identify bacterial origins of the blood microbiome. To test the feasibility
of using our BEV DNA isolation protocol to profile the blood microbiome of healthy and
diseased individuals, we undertook a pilot study to compare the blood microbiome of
healthy individuals and patients with CD and UC. To our knowledge the presence of BEVs
and associated blood microbiome profile in patients with IBD has not been previously
investigated. Using 16S rRNA gene sequencing, we found that the BEV-associated blood
microbiota composition was not distinct between IBD, HC, or protocol control groups.
As an initial experiment prior to the main study, we compared two commonly used
EV isolation methods: ultracentrifugation and SEC [53,54] as well as boiling, which is
frequently used for plasma BEV-associated DNA isolation [26,27,55–57]. Based upon the
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relative amplification of the V3–V4 region of the 16S rRNA gene per mL of plasma, SEC
and boiling were optimal for maximal DNA isolation (Figure 3a).
Although SEC using IZON qEV columns successfully separated EVs from protein
contaminants (Appendix A Figure A2), the boiling protocol was chosen as it had the lowest
level of bacterial DNA contamination in the protocol control (water) sample (Figure 3a).
The boiling protocol is also the least labor intensive and requires no specialist equipment
such as SEC columns or an ultracentrifuge, which are important factors for potential use
of the protocol as a high throughput, routine blood test in a clinical setting. In addition,
TEM imaging confirmed that boiling reduced levels of contaminating extracellular protein
aggregates (Figure 3c). It should be noted that if detailed functional, biochemical, or
biophysical studies of highly purified BEVs are required, more stringent protocols such as
that developed by Tulkens et al. using SEC and/or density-gradient centrifugation should
be implemented [52,58,59].
Extracellular DNA can cause contamination issues in sequencing studies and is often
ignored or overlooked in BEV-associated DNA sequencing protocols. To eliminate this
potential problem, we pre-treated all plasma samples with DNase I prior to boiling and
DNA isolation, the efficiency of which was confirmed by spiking plasma samples with
DNA from a non-gut related bacterium, B. subtilis (Figure 3c). This data highlights the
importance of the removal of extracellular DNA in low-biomass samples such as plasma
prior to 16S rRNA gene amplification and sequencing.
Another limitation of using 16S rRNA gene sequencing-based analysis of these low-
biomass samples is the potential for contamination from laboratory reagents [60–62]. We
found that bacterial DNA appears to be introduced after the EV lysis stage, likely from
the SDS lysis buffer and DNA isolation kit reagents (Appendix A Figure A1), rendering
the protocol control samples indistinguishable from plasma samples in terms of α- and
β-diversity. This contamination from DNA kits is often referred to as the ‘kit-ome’ and
is a common problem in low-biomass sequencing studies [60,62] which can result in the
microbiome between control and disease samples being indistinguishable [61,63–65], as
found in this study.
Therefore, our pilot study highlights that appropriate controls need to be included to
identify sources of laboratory contamination and sequencing data needs to be interpreted
with care. For this study, we aimed to minimise laboratory contamination by processing
all plasma and protocol control samples as a single batch for EV isolation, PCR, and se-
quencing to produce robust and reliable results and avoid any batch-effect in processing
and sequencing. Additionally, our 16S rRNA gene sequencing data analysis first involved
identifying and removing the representative protocol control reads from the plasma reads.
This enabled us to identify the ‘kit-ome’ as a potential source of microbial DNA. Our find-
ing of water-borne bacterial genera such as Pseudomonas, Stenotrophomonas, Xanthomonas,
Ralstonia, and Bacillus, as well as soil and plant associated bacteria such as Spingobacteriaceae,
Bradyrhizobiaceae, Methylbacterium, and Phyllobacreriaceae in the protocol control samples,
mirrors that of previous studies [61,64–66]. Therefore, future studies will need to eliminate
these sources of contamination alongside appropriate protocol controls.
The co-isolation of host derived EVs, including exosomes containing host DNA, can
also reduce the purity of BEV isolates. However, separating low-abundance BEVs from
mammalian EVs, proteins, and lipid particles is challenging [67]. The most abundant
particles in plasma are lipoproteins, with only <1% being identified as EVs by a lipid
bilayer [50,68]. The majority of the identified plasma particles are therefore likely to be
lipoproteins and soluble proteins. Additionally, the overlap between EV and BEV size
(30–1000 nm for EVs and 20–250 nm for BEVs) [52,69,70] makes separation by size difficult.
Using NTA, we found that prior to processing, plasma contained 2.8 × 1012 nanoparticles
per mL with a mean particle size of 94 nm (Figure 2a). This size distribution could not
be confirmed in non-processed plasma using TEM due to the presence of contaminating
proteins which adhered to the EM grids (Appendix A Figure A2b). However, imaging
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of a patient plasma sample purified by SEC revealed intact, spherical vesicles with the
characteristic cup-shape (Figure 2b) morphology of BEVs [16,18,20,71].
Therefore, future studies should focus on both increasing the concentration of BEV-
associated DNA from plasma samples by using a greater starting volume of plasma
(>1 mL) and including additional BEV specific isolation/concentration steps such as
density-gradient centrifugation, which can separate BEVs from mammalian EVs, and
liposomes or antibody-mediated depletion (immunomagnetic separation), which can sepa-
rate mammalian EVs from BEVs.
Although the 16S rRNA analysis of BEV DNA showed that there was no signifi-
cant difference in the blood microbiota richness, diversity, or community composition
between groups, the presence of BEV DNA originating from dominant gut bacteria such as
Bacteroides, Bifidobacterium, Campylobacter, Cutibacterium, Escherichia_Shigella, and Streptococ-
cus [72,73] in the plasma of both IBD patients and healthy individuals suggests luminal
antigens and bacterial products can translocate across the epithelial barrier and access the
circulatory system. As the findings described here in our pilot study were from patients
with established but non-active disease, it is not unexpected that there were no significant
differences in the origin of circulating BEVs between groups. In IBD patients with active
disease and a compromised intestinal epithelial barrier, it would be predicted that a greater
number of luminal BEVs translocating from the gut to the circulation would be identified
that might mirror the gut microbiota [74].
Our rapid BEV DNA isolation protocol would facilitate and aid future studies ex-
amining larger cohorts of patients, including those pre-diagnosis, pre-symptomatic, and
post-diagnosis experiencing active, symptomatic disease that are required to test this hy-
pothesis further. Comparison of our BEV blood test with traditionally used inflammatory
biomarkers would provide further evidence for the expediency of our novel technology. A
longitudinal study following patients’ pre-diagnosis through to diagnosis and treatment
would also be invaluable.
5. Conclusions
We have developed a rapid, cost-effective protocol to isolate BEV-associated DNA
and used 16S rRNA gene sequencing to identify bacterial origins of the blood microbiome.
From our pilot study, using small sample numbers, it was not possible to detect significant
differences in microbial composition of plasma derived BEVs from healthy individuals
versus IBD patients. Our simple protocol provides the means of undertaking a larger study
to test the hypothesis that the gut microbiota of IBD patients is reflected in plasma BEVs
and determine if they may be of use as a diagnostic aid in IBD.
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Appendix A
Figure A1. Taxonomic profile of the protocol control samples. (a) The relative abundance chart
shows the top 10 most dominant taxa at the genus level. (b) Microbial abundance at the genera level
(counts) of each protocol control sample reduces as each step of the protocol is removed. (c) Microbial
richness measured by α-diversity also reduces as each step of the protocol is removed (ASV-level
Observed Index: number of unique ASVs observed per sample).
Figure A2. Plasma size exclusion chromatography (SEC) fractionation using qEV (IZON) columns.
(a) Example fractionation profile from a qEV/35 nm SEC column loaded with 1 mL plasma. Con-
centration of particles (red bars) was measured using nanoparticle tracking analysis (NTA) with a
ZetaView twin instrument (Particle Metrix). Total protein was measured using a BCA Protein Assay
Kit for low concentrations (Abcam, blue points). The first 3 mL are void containing no particles
(grey, void zone), plasma EVs typically elute in the next 3 mL (EV zone, red), and proteins in the
remaining 7 mL (protein zone, blue). Sample n = 1. (b) Example of a plasma sample imaged using
transmission electron microscopy (TEM) pre- and post-processing using a qEV/35 nm SEC column.
Post-processing, extracellular proteins (white haze) are removed and intact, spherical vesicles can be
visualized. Scale bar (200 nm).
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